Actively Recruiting
Lung Innate Immunity and Microbiome After Tuberculosis Exposure
Led by University of Oxford · Updated on 2025-01-22
50
Participants Needed
3
Research Sites
215 weeks
Total Duration
On this page
Sponsors
U
University of Oxford
Lead Sponsor
U
University College, London
Collaborating Sponsor
AI-Summary
What this Trial Is About
To characterise the innate pulmonary immune response and respiratory microbiome after recent exposure to M.tb and to evaluate how differences determine the outcome of M.tb exposure
CONDITIONS
Official Title
Lung Innate Immunity and Microbiome After Tuberculosis Exposure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18-65 years
- Resident in or near London or Oxford for the duration of the study period
- Provide written informed consent
- Willing to allow investigators to review NHS care records, medical history, blood results, and radiographs
- Able and willing to comply with all study requirements
- Have undergone TB screening through NHS services (including IGRA testing and chest X-ray if indicated)
- Close contact with a sputum smear positive TB case within the last 12 weeks
You will not qualify if you...
- Participation in another research study involving an investigational product in the 30 days before or during this study
- History of anaphylaxis or allergies likely to be worsened by study procedures
- Poorly controlled airways disease, current cancer (except certain skin or cervical conditions), bleeding disorders, or drug/alcohol abuse
- Significant autoimmune conditions or immunodeficiency, including HIV
- Previous diagnosis or treatment for active or latent TB
- Evidence of current active TB disease clinically, radiologically, or by lab tests
- Previous receipt of investigational TB vaccines or aerosolised BCG
- Significant abnormalities in lung function tests
- Use of oral, inhaled, or systemic steroids for more than 14 days in the last 6 months or other immunosuppressive agents
- Use of antibiotics in the past 4 weeks
- Receipt of immunoglobulins or blood products within 3 months before the study
- Receipt of live vaccines within 28 days or non-live vaccines within 14 days before enrollment
- Pregnancy or intention to become pregnant during the study
- Other significant diseases or conditions that may affect safety or study participation
- For Group C: history of close contact with a TB case or previous contact tracing by TB services
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Churchill Hospital
Oxford, Oxfordshire, United Kingdom, OX3 7LE
Actively Recruiting
2
Centre for Clinical Vaccinology and Tropical Medicine
Oxford, Oxon, United Kingdom, OX3 9DZ
Actively Recruiting
3
Grove Building, Royal Free NHS Foundation Trust
London, United Kingdom, NW3 2QG
Actively Recruiting
Research Team
T
Timothy Fredsgaard-Jones, MBBS
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here